Reid J A, Wolsley C, Lau L L, Hannon R J, Lee B, Young I S, Soong C V
Regional Vascular and Endovascular Unit, Belfast City Hospital, Belfast, UK.
Eur J Vasc Endovasc Surg. 2005 Nov;30(5):464-8. doi: 10.1016/j.ejvs.2005.05.007.
Carotid intima media thickness (IMT) is a good indicator of the severity of atherosclerotic disease. Statins have been found to reduce carotid IMT in patients with hypercholesterolaemia. The aim of this study was to investigate if pravastatin is effective in reducing IMT in normocholesterolaemic patients with carotid artery disease.
Patients with carotid artery stenosis and normal cholesterol levels who were not on a statin, were recruited. Patients were randomised to receive pravastatin or placebo daily. Serum concentration of cholesterol and IMT of common carotid arteries were measured before randomisation and at 3 monthly intervals thereafter, for 9 months. IMT was analysed to give the mean of a standardised 2 cm of the common carotid artery (CCA). Results are expressed as median (IQR) and comparison made using the Wilcoxon signed ranks test.
Fifty-four patients were examined. Twenty-eight patients were randomised to active treatment. There was no difference in demographic details and co-morbid states between the two groups. A significant reduction in cholesterol concentration was observed from 3 months in patients randomised to the pravastatin group [5.14(4.72-5.88) vs. 4.11(3.44-5.33), p < 0.05], while there was also a significant decrease in combined IMT form 6 months [1.53(1.36-1.87) vs. 1.41 (1.33-1.78), p < 0.05].
The results demonstrate that pravastatin reduces intima media thickness of the common carotid artery in normocholesterolaemic patients with moderate carotid stenosis.
颈动脉内膜中层厚度(IMT)是动脉粥样硬化疾病严重程度的一个良好指标。已发现他汀类药物可降低高胆固醇血症患者的颈动脉IMT。本研究的目的是调查普伐他汀对降低患有颈动脉疾病的正常胆固醇水平患者的IMT是否有效。
招募未服用他汀类药物、胆固醇水平正常且患有颈动脉狭窄的患者。患者被随机分为每日接受普伐他汀或安慰剂治疗。在随机分组前及之后每3个月测量一次血清胆固醇浓度和颈总动脉的IMT,为期9个月。对IMT进行分析,得出颈总动脉(CCA)标准化2厘米长度的平均值。结果以中位数(四分位间距)表示,并使用Wilcoxon符号秩检验进行比较。
检查了54名患者。28名患者被随机分配至积极治疗组。两组在人口统计学细节和合并疾病状态方面无差异。随机分配至普伐他汀组的患者从3个月起胆固醇浓度显著降低[5.14(4.72 - 5.88)对4.11(3.44 - 5.33),p < 0.05],同时从6个月起合并IMT也显著降低[1.53(1.36 - 1.87)对1.41(1.33 - 1.78),p < 0.05]。
结果表明,普伐他汀可降低患有中度颈动脉狭窄的正常胆固醇水平患者的颈总动脉内膜中层厚度。